Treatment modifications in tumour necrosis factor-α (TNF)-based isolated limb perfusion in patients with advanced extremity soft tissue sarcomas

Keyphrases

• Tumor Necrosis Factor-α 100%
• Treatment Modification 100%
• Isolated Limb Perfusion 100%
• Extremity Soft Tissue Sarcoma 100%
• Melphalan 25%
• High Dose 25%
• Hospital Stay 25%
• Perfusion 25%
• Local Toxicity 25%
• Clinical Examination 12%
• Clinical Outcomes 12%
• Treatment Modalities 12%
• Treatment Options 12%
• Effective Treatment 12%
• Clinical Response 12%
• Single-center Experience 12%
• Treatment Outcome 12%
• Local Control 12%
• Response Evaluation 12%
• Amputation 12%
• Local Recurrence Rate 12%
• Reduced Dose 12%
• Pathological Response 12%
• Iliac 12%
• Cardiac Magnetic Resonance Imaging (cMRI) 12%
• Two-period 12%
• Limb-threatening 12%
• Clinical Response Rate 12%

Medicine and Dentistry

• Soft Tissue Sarcoma 100%
• Limb Perfusion 100%
• Tumor Necrosis 100%
• Melphalan 25%
• Drug Megadose 25%
• Clinical Examination 12%
• Tumor Necrosis Factor 12%
• Magnetic Resonance Imaging 12%
• Recurrence Risk 12%
• Limb 12%
• Amputation 12%
• Effective Treatment 12%
• Treatment Option 12%
• Treatment Modality 12%

Nursing and Health Professions

• Soft Tissue Sarcoma 100%
• Limb Perfusion 100%
• Tumor Necrosis 100%
• Drug Megadose 25%
• Perfusion 25%
• Melphalan 25%
• Nuclear Magnetic Resonance Imaging 12%
• Clinical Outcome 12%
• Amputation 12%
• Recurrence Risk 12%
• Tumor Necrosis Factor 12%
• Clinical Examination 12%